2021
Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies
Shallis RM, Bewersdorf JP, Swoboda DM, Wei W, Gowda L, Prebet T, Halene S, Pillai MM, Parker T, Neparidze N, Podoltsev NA, Seropian S, Sallman DA, Gore SD, Zeidan AM. Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. Clinical Lymphoma Myeloma & Leukemia 2021, 21: e483-e487. PMID: 33551344, DOI: 10.1016/j.clml.2021.01.003.Peer-Reviewed Original Research
2020
Type 3 Inositol 1,4,5‐Trisphosphate Receptor Is Increased and Enhances Malignant Properties in Cholangiocarcinoma
Ueasilamongkol P, Khamphaya T, Guerra MT, Rodrigues M, Gomes DA, Kong Y, Wei W, Jain D, Trampert DC, Ananthanarayanan M, Banales JM, Roberts LR, Farshidfar F, Nathanson MH, Weerachayaphorn J. Type 3 Inositol 1,4,5‐Trisphosphate Receptor Is Increased and Enhances Malignant Properties in Cholangiocarcinoma. Hepatology 2020, 71: 583-599. PMID: 31251815, PMCID: PMC6934938, DOI: 10.1002/hep.30839.Peer-Reviewed Original ResearchConceptsType 3 inositolCCA cellsIntracellular calcium ionsPathogenesis of malignanciesCCA cell linesCommon malignancyPoor prognosisTrisphosphate receptorMalignant featuresMitochondrial CaITPR3 expressionCholangiocarcinomaRegions of ERMalignant propertiesCCA samplesCell proliferationCholangiocytesEndoplasmic reticulumType of tissueMalignancyCell linesITPR3PathogenesisCell deathCell migration